Commentary|Videos|November 19, 2026

Cefiderocol Holds Activity Against Resistant Pseudomonas in VAP

Fact checked by: Ashley Gallagher, MA

Sean Nguyen, PharmD, discusses SENTRY data showing cefiderocol activity against resistant Pseudomonas VAP isolates and what it means for ICU care.

Captions are auto-generated.

Cefiderocol (Fetroja; Shionogi) maintained high susceptibility rates against highly resistant Pseudomonas aeruginosa (P. aeruginosa) isolates from patients with ventilator-associated pneumonia (VAP), according to a global surveillance study.1

The data were presented at IDWeek in Washington, DC, from October 21 to 24, 2026. P. aeruginosa is a leading cause of VAP and a significant driver of mortality in critically ill patients. Increasing resistance to contemporary beta-lactam–beta-lactamase inhibitor (BL-BLI) therapies has reduced their effectiveness as treatment options for highly resistant P. aeruginosa infections.1

Of 1400 P. aeruginosa VAP isolates collected in the US and Europe through the SENTRY Antimicrobial Surveillance Program from 2020 to 2024, 97.9% to 99.5% were susceptible to cefiderocol across 3 sets of interpretive criteria (FDA, EUCAST, and CLSI). Cefiderocol susceptibility stayed above 91% (CLSI) among isolates nonsusceptible to the comparator BL-BLIs and was 93.3% among 30 metallo-beta-lactamase–producing isolates, whereas comparator BL-BLI susceptibility was 42% or lower in these resistant subsets.1

Although the evolution of drug resistance isn't uncommon, it can significantly narrow the choice of antibiotics used to treat critically ill patients, Sean Nguyen, PharmD, senior medical director of infectious diseases at Shionogi and lead study author, said in an interview with The American Journal of Managed Care®. Those narrowing options create obstacles for clinical decisions in the intensive care unit, where appropriate treatment needs to be started early, and delays can lead to worsening outcomes, he explained.

"It's really important to understand the resistance patterns, where commonly used antibiotics share vulnerabilities to resistance mechanisms, [and] where clinicians may need to understand alternatives available to them when they have these patients present," Nguyen said.

Even so, treatment decisions are based on multiple factors, such as a patient's clinical status, risk factors for gram-negative multidrug resistance, previous antibiotic exposure, and local susceptibility patterns. Balancing these factors, clinicians often begin with an established treatment option and then adjust therapy as more data become available, Nguyen explained.

"Antibiotic stewardship principles emphasize using antibiotics appropriately and preserving important antibiotics, where antibiotics can be used at the right place and the right time," he said. "So the key is to identify what risk factors are present so they can recognize which patients may benefit when using appropriate antibiotics earlier to avoid bad outcomes."

Reference

1. Nguyen ST, DeJonge BLM, Simon S, et al. Cefiderocol activity across highly resistant Pseudomonas aeruginosa ventilator-associated pneumonia isolates: a global surveillance study of SENTRY 2020–2024. Presented at: IDWeek 2026; October 21-24, 2026; Washington, DC. Poster 459.


Related to this article